1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
SURPASS, Simulation-augmented, Real-time Platform Adaptive Seamless Trials, is an ARPA-H program launched under solicitation ARPA-H-SOL-26-164 to rebuild drug and biologic evaluation around predictive computational models rather than around sequential standalone trials.
The target is the decade-long, serially staged development path: SURPASS seeks perpetual adaptive platform trials that combine predictive computational models, shared trial infrastructure, common control groups and real-time analysis so that drugs and biologics can be evaluated faster, at lower cost and with fewer participants than conventional approaches.
ARPA-H is explicit that it wants cross-disciplinary teams spanning statistics, AI, and clinical trial design, operations and regulation, which is the distinguishing requirement; a team strong in machine learning but without trial operations and regulatory expertise will not be competitive, and nor will a trials group bolting on a modelling subcontractor.
The simulation component is the technical core, using mechanistic and learned models of disease progression and treatment response to augment real enrolled participants, which is also what makes the regulatory dimension unavoidable rather than optional. The process is two-stage: a required Solution Summary is due 30 November 2026, ARPA-H returns feedback, and invited full proposals are due 22 January 2027.
An optional informational webinar was held 15 October 2026 and an optional Proposers' Day on 6 November 2026, and ARPA-H maintains a teaming directory for consortium formation.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Complete eligibility requirements are set out in the solicitation documents posted on SAM.gov rather than on the program overview page, and ARPA-H has not published restrictions in the public summary. Based on the agency's standard practice for program solicitations issued as Other Transaction Agreements, applications are generally open to academic institutions, non-profits, for-profit entities including small businesses, and consortia thereof, with Federally Funded Research and Development Centers and national laboratories typically restricted to subaward or collaborator roles; applicants must verify this against the notice rather than assume it. The substantive eligibility filter is the composition requirement: ARPA-H wants cross-disciplinary teams covering statistics, AI, and clinical trial design, operations and regulation, and the program's dependence on shared trial infrastructure and common control groups means a credible proposal needs committed clinical sites and a plausible regulatory engagement strategy at submission, not as a later deliverable. Because awards are Other Transaction Agreements, institutional contracting and sponsored-programs offices should be engaged before the Solution Summary stage; other-transaction terms on data rights, intellectual property and cost allowability are negotiated and differ materially from standard grant terms. The binding sequence is the required Solution Summary due 30 November 2026, ARPA-H feedback, then the full proposal due 22 January 2027 submitted through the ARPA-H Solutions site, which requires sign-in. There is no route to the full proposal stage without the Solution Summary. Confirm the full requirements in the official notice before applying.
The current listing shows ARPA-H has not published an award ceiling, award floor or total program budget for SURPASS. The program overview and the HHS launch announcement both describe a five-year program with multiple Other Transaction Agreement awards anticipated, and direct applicants to the solicitation documents on SAM.gov for funding detail; secondary coverage confirms that no budget or award ceiling was published alongside the notice. amount_min and amount_max are therefore recorded as unknown rather than estimated, and applicants should not infer a ceiling from comparable ARPA-H programs because other-transaction awards at the agency have ranged across two orders of magnitude. What is known about the financial structure is more useful than a headline number: awards are Other Transaction Agreements rather than grants or standard cooperative agreements, which means cost principles, intellectual property terms, milestone payment schedules and data rights are negotiated per award rather than fixed by regulation, and ARPA-H routinely structures them as go or no-go milestone tranches. Teams should budget for the full five-year arc with explicit decision gates and should expect to justify cost share or in-kind contribution from the trial-infrastructure partners. Confirm current figures in the solicitation attachments on SAM.gov under ARPA-H-SOL-26-164 before planning. Verify award ceilings, matching requirements, and allowable costs in the official notice.
Applications for ARPA-H SURPASS Simulation-Augmented, Real-Time Platform Adaptive Seamless Trials (ARPA-H-SOL-26-164) for AI and Predictive Computational Models in Clinical Trials are due January 22, 2027. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
ARPA-H SURPASS Simulation-Augmented, Real-Time Platform Adaptive Seamless Trials (ARPA-H-SOL-26-164) for AI and Predictive Computational Models in Clinical Trials is funded by Advanced Research Projects Agency for Health (ARPA-H), U.S. Department of Health and Human Services. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
The ONR Long Range Broad Agency Announcement (N00014-25-S-B001) is the Office of Naval Research's primary mechanism for soliciting research proposals across all naval science and technology priority areas. The BAA accepts proposals on a rolling basis through September 30, 2026 and covers ONR's full spectrum of research interests with particular emphasis on AI-related topics including autonomous maritime systems, human-machine teaming, machine learning for sensor fusion, cooperative autonomous swarm technology, undersea autonomy, and AI-enabled decision superiority. Proposals can be funded through multiple mechanisms including individual investigator grants, the Young Investigator Program (~$510K over 3 years for early-career faculty), and Multidisciplinary University Research Initiative (MURI) awards ($1.5M/year for 3-5 years for research teams). ONR recommends contacting relevant program officers before submitting to discuss alignment with current research priorities. The BAA supports basic research (6.1), applied research (6.2), and advanced technology development (6.3) across the full range of naval-relevant science and engineering disciplines.
PRIMED-AI is a new NIH Common Fund programme, Precision Medicine with AI: Integrating Imaging with Multimodal Data, which combines medical imaging with other health data to build AI-powered clinical decision support tools for personalised medicine. This opportunity, RFA-RM-27-014, funds the programme's Validation Center: a dedicated hub that independently evaluates and characterises the AI-enabled, image-based multimodal clinical decision support tools developed elsewhere in the consortium. The structural logic matters for applicants. NIH has separated tool-building from tool-validation and is paying separately for the second, which signals institutional recognition that self-reported performance claims from developing teams are not sufficient evidence for clinical AI. The Center's remit covers verification, validation, interoperability and uncertainty quantification, so the deliverable is a reproducible evaluation capability rather than a set of papers. It operates as a U54 cooperative agreement, meaning NIH staff are substantively involved and the Center must work in concert with the PRIMED-AI Logistics Center and the Data-to-Model and Model-to-Clinic award recipients. The RFA was released on 30 June 2026 with applications due 2 October 2026. For academic groups that have built credible AI evaluation methodology, particularly in radiology, imaging informatics or biostatistics, this is an unusually direct route to becoming the reference evaluator for a major federal AI health programme, and the position carries influence over how clinical AI performance gets measured well beyond the life of the award.
RFA-RM-27-015 funds a single Logistics Center as the coordinating hub of the NIH Common Fund's PRIMED-AI program, Precision Medicine with AI: Integrating Imaging with Multimodal Data. The award is a cooperative agreement, meaning substantial NIH scientific and programmatic involvement is built in rather than incidental, and it is administered by NIBIB on behalf of the Common Fund. The Center operates through three integrated cores: Administration, which runs the steering committees and develops consortium policies; Evaluation, which assesses progress across the funded portfolio; and Outreach, which maintains a web portal for sharing AI-based clinical decision support tools and facilitates engagement between researchers, clinicians and patient communities. The strategic point for applicants is that this is the only coordinating award in a multi-award program whose other components, the Data-to-Model Academic-Industrial Partnerships, Model-to-Clinic and Multi-use Frameworks Playbook RFAs, are separately competed and separately funded. The Logistics Center therefore does not generate its own AI models; it is scored on its capacity to run a consortium, set data and tool-sharing policy, and build infrastructure that makes other teams' clinical decision support tools discoverable and reusable. Applications are due by 5:00 PM local time of the applicant organization on the date specified for the relevant review cycle, with an earliest project start date of 2 October 2026 and a maximum project period of five years.
The STOMP program funds measurement tools and removal therapies for microplastics in human tissue. Proposals due June 22. Eligibility, phases, and strategy.
Read articleSTACK, COMMONS, and CINCH had named primes and September start dates by the time HHS announced them. Evidence Health holds $91.08M of the package; only SURPASS is open, with solution summaries due November 30, 2026.
Read articleThe Emerging Health Innovators solicitation drops on SAM.gov by the end of September 2026 with 16 named topic areas, an eight-year terminal-degree ceiling, and an eligibility screen that bars national labs, FFRDCs, UARCs, and anyone who has ever led an ARPA prime award. Proposers' Day is October 13. Here is how to read the design.
Read article